- GSK’s Nucala (mepolizumab) received a positive reimbursement recommendation with conditions from CDA-AMC for adults with COPD characterized by raised blood eosinophils inadequately controlled by ICS/LABA/LAMA triple therapy
- The recommendation follows Health Canada’s June 2026 approval and marks a step toward public funding, with provincial and territorial governments making final coverage decisions
- The recommendation is supported by MATINEE, METREX and METREO Phase III data. In MATINEE, Nucala demonstrated a statistically significant reduction in the annualized rate of moderate/severe exacerbations versus placebo
- MATINEE also showed a numerical reduction in exacerbations requiring emergency visits or hospitalization, although the endpoint did not meet statistical significance
Takeaways:
CDA‑AMC’s positive, conditional reimbursement recommendation for Nucala (mepolizumab) in adults with COPD and raised blood eosinophils who remain uncontrolled on ICS/LABA/LAMA triple therapy is a key step toward public funding, though final coverage will depend on provincial/territorial decisions and confidential price negotiations. The trial results positions Nucala as a targeted add‑on for the eosinophilic COPD subgroup rather than broad COPD use.
Source: CA Newswire
